Drugs / Inactivated Rotavirus Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06350058 | Aug 2021 → Nov 2023 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06080906 | Oct 2023 → Feb 2025 | Rotavirus infection, diarrheal disease | Institute of Medical Biology, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated rotavirus vaccine | “This study is a randomized, double-blinded, placebo-controlled phase 2 clinical trial to evaluate the immunogenicity and safety of Inactivated Rotavirus Vaccine (IRV) in...” NCT06080906 ↗ |
| Known as | IRV | “This study is a randomized, double-blinded, placebo-controlled phase 2 clinical trial to evaluate the immunogenicity and safety of Inactivated Rotavirus Vaccine (IRV) in...” NCT06080906 ↗ |
| Modality | Vaccine | “Inactivated Rotavirus Vaccine (IRV)” NCT06080906 ↗ |
| Route | Intramuscular | “will receive an injection of the vaccine or placebo in the anterolateral midthigh or deltoid muscle of the upper arm” NCT06080906 ↗ |